# AIM ImmunoTech Inc. (AIM) · Edgar & Edgarette company card

> AIM ImmunoTech (AIM) saw revenue fall 48.2% in FY2025 to $0 million, operating margin -13255% against a -15.8% median for biological products, (no diagnostic substances), equity -169% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 946644 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AIM) · [JSON](https://www.pops4.com/boards/company/AIM.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $88,000 |
| Revenue growth, 1 year | -48.2% |
| Revenue growth per year | -10.1% |
| Operating margin | -13254.5% (prior year -11630.6%) |
| Net margin | -15861.4% |
| Operating cash flow | −$11M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $3M |
| Long-term debt | $4M |
| Total assets | $6M |
| Total equity | −$10M |
| Equity ÷ assets | -169.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -266.06 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$11.0M in FY2025); operating loss: a margin of -13254.5% in FY2025; revenue is hard to predict: its 80% range is ±57%

## Edgarette's reading

Exposure: revenue $88K (FY2025), total debt $4.5M. Experience: revenue down 48.2% on the year, down 10.1% a year over 4 years; operating margin -13254.5%, down from -11630.6%. Soundness: equity -169.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $31K and $114K next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $28K to $125K. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -13254.5% against a -15.8% median; growth -48.2% against 21.4%.

Range logged 2026-09-25, receipt 834e7dc2e2197aa4, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-Q Late quarterly report notice: 1, latest 2025-11-17 ([filing](https://www.sec.gov/Archives/edgar/data/946644/000149315225023724/0001493152-25-023724-index.htm))

## Recent filings

- DEF 14A · filed 2026-09-30 · [filing](https://www.sec.gov/Archives/edgar/data/946644/000149315226045102/0001493152-26-045102-index.htm)
- 8-K · filed 2026-09-14 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/946644/000149315226042592/0001493152-26-042592-index.htm)
- 8-K · filed 2026-09-10 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/946644/000149315226042196/0001493152-26-042196-index.htm)
- 8-K · filed 2026-09-04 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/946644/000149315226041537/0001493152-26-041537-index.htm)
- 8-K · filed 2026-08-11 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/0001493152-26-036996-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/0001493152-26-036753-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000946644.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=946644

## Cite

POPS4, Edgar & Edgarette: AIM ImmunoTech Inc. (AIM) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/AIM. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.